DA-8010 5mg

DRUG4 trials

Sponsors

Dong-A ST Co., Ltd.

Conditions

HealthyOveractive Bladder

Phase 1

Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults

CompletedNCT05991401

Dong-A ST Co., Ltd.Healthy

Start: 2023-08-18End: 2023-11-17Updated: 2024-01-25

Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

CompletedNCT05992428

Dong-A ST Co., Ltd.Healthy

Start: 2023-08-22End: 2023-12-05Updated: 2024-01-25

Phase 2

A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder

CompletedNCT03566134

Dong-A ST Co., Ltd.Overactive Bladder

Start: 2018-07-10End: 2019-12-27Updated: 2020-02-07

Phase 3

A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

CompletedNCT05282069

Dong-A ST Co., Ltd.Overactive Bladder

Start: 2022-05-12End: 2024-05-29Updated: 2024-06-26

Related Papers

Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study

International Neurourology Journal2022-06-299 citations